Allergic transfusion reactions are immune-mediated hypersensitivity responses occurring during or within 4 hours of blood product transfusion, caused by histamine and other mediators released from mast cells and basophils. [1] They are among the most common transfusion reactions, with the highest incidence associated with platelet transfusions (~302 per 100,000 units). [1] Most are mild (cutaneous only), but severe anaphylactic reactions occur at a rate of ~8 per 100,000 units and can be life-threatening. [1]
1. History
- Temporal relationship: Onset during or within 4 hours of transfusion; anaphylaxis typically within minutes [1]
- Symptom characterization: Pruritus, urticaria/hives, flushing, localized angioedema; in severe cases — dyspnea, wheezing, chest tightness, throat swelling, abdominal cramping, hypotension [1]
- Blood product type: Platelet transfusions carry the highest risk; also occurs with RBCs, plasma, and cryoprecipitate [2]
- Prior transfusion history: Number of prior transfusions, any previous reactions and their severity, prior premedication used [3]
- Atopic history: Personal history of allergies, asthma, eczema, food allergies
- Known IgA deficiency: Critical to elicit — IgA-deficient patients with anti-IgA antibodies are at risk for anaphylaxis [1][4]
- Important negatives: Absence of fever/chills (helps distinguish from febrile nonhemolytic transfusion reaction [FNHTR] and hemolytic reactions), absence of respiratory distress/pulmonary edema (helps distinguish from TACO/TRALI) [2]
2. Alarm Features
- Anaphylaxis: Bronchospasm, stridor, laryngeal edema, hypotension, tachycardia, cardiovascular collapse [1]
- Rapid onset (within minutes of starting transfusion) with systemic symptoms
- Respiratory distress — must differentiate from TRALI (bilateral pulmonary infiltrates, hypoxemia within 6 hours) and TACO (fluid overload, elevated BNP) [2][5]
- Hemodynamic instability — consider acute hemolytic transfusion reaction (fever, flank pain, dark urine, DIC) [1][6]
- Sense of impending doom — classically associated with acute hemolytic reactions but can occur in anaphylaxis [6]
- Any reaction that progresses beyond isolated cutaneous findings warrants immediate transfusion discontinuation [1]
3. Medications
Acute Treatment
- Mild (cutaneous only): Diphenhydramine 25–50 mg IV/PO (Grade 1A) — if symptoms resolve, transfusion may be cautiously restarted at a reduced rate [1]
- Anaphylaxis: Epinephrine IM (0.3–0.5 mg of 1:1,000 in adults) is first-line (Grade 1A) [1]
- Second-line agents for anaphylaxis: [1]
- H1 antihistamine (diphenhydramine 25–50 mg IV)
- H2 antihistamine (famotidine 20 mg IV)
- Bronchodilator (albuterol nebulized)
- IV corticosteroid (hydrocortisone 200 mg or methylprednisolone 125 mg)
Prevention/Premedication
- Routine premedication with acetaminophen and antihistamines does not prevent allergic reactions in unselected patients (RR 1.37, 95% CI 0.81–2.31 for allergic reactions) [7-8]
- In patients with a history of severe ATR, premedication with antihistamines, regular antiallergy medications, and washed/volume-reduced products were associated with significantly fewer reactions [3]
- Washed blood products (plasma removal) reduce incidence in patients with recurrent moderate-to-severe reactions (Grade 1C) [1][9]
- Platelets stored in additive solutions (reduced plasma content) are an alternative [1]
- Omalizumab has been reported as a successful adjunct in refractory severe platelet-induced anaphylaxis [10]
Contraindicated/Cautions
- Avoid restarting transfusion if symptoms recur or progress beyond cutaneous findings [1]
- NSAIDs are not indicated for allergic reactions (unlike FNHTR where antipyretics are used)
4. Diet
- Not directly applicable to acute management
- Notably, food allergens in donor blood (from a donor who recently consumed allergenic foods) have been implicated as a cause of anaphylaxis in sensitized recipients — a recognized but uncommon mechanism [9]
- No specific dietary restrictions for the patient post-reaction
5. Review of Systems
- Skin: Urticaria, pruritus, flushing, angioedema, maculopapular rash [2]
- Respiratory: Dyspnea, wheezing, stridor, cough, chest tightness
- Cardiovascular: Lightheadedness, palpitations, syncope (suggests anaphylaxis)
- GI: Nausea, vomiting, abdominal cramping (anaphylaxis)
- Constitutional: Notably, fever is typically absent in isolated allergic reactions — its presence should prompt consideration of FNHTR, hemolytic reaction, or septic transfusion reaction [2]
- Genitourinary: Dark urine (hemolytic reaction), flank pain (hemolytic reaction) — important negatives [6]
6. Collateral History and Family History
- Prior transfusion records: Number of transfusions, documented reactions, premedication protocols used, blood bank records of prior workups [3]
- IgA deficiency: May be familial; family history of immunodeficiency or recurrent infections
- Atopic family history: Allergies, asthma, eczema
- Haptoglobin deficiency: Rare hereditary condition associated with anaphylactic transfusion reactions (more common in East Asian populations) [1]
- Social context: Patients receiving chronic transfusions (sickle cell disease, thalassemia, MDS, hematologic malignancies) are at higher cumulative risk
7. Risk Factors
- Platelet transfusions — highest incidence of allergic reactions among all blood products [1-2]
- Prior allergic transfusion reaction — strongest predictor of recurrence [3]
- Atopic history (asthma, allergic rhinitis, eczema, food allergies)
- IgA deficiency with anti-IgA antibodies [1][4]
- Haptoglobin deficiency with anti-haptoglobin antibodies [1]
- Multiple prior transfusions — cumulative sensitization
- Non-leukoreduced products — higher cytokine and mediator content [11]
- Longer storage duration of blood products (increased histamine and bioactive lipid accumulation) [11]
8. Differential Diagnosis
- Febrile nonhemolytic transfusion reaction (FNHTR): Fever ≥1°C rise, chills/rigors; no urticaria; most common transfusion reaction [2][8]
- Acute hemolytic transfusion reaction: Fever, flank/back pain, dark urine, hypotension, DIC — a medical emergency; positive DAT, hemoglobinemia [1][6]
- Transfusion-related acute lung injury (TRALI): Acute respiratory distress, bilateral pulmonary infiltrates, hypoxemia within 6 hours; no evidence of circulatory overload [4-5]
- Transfusion-associated circulatory overload (TACO): Dyspnea, orthopnea, pulmonary edema, elevated BNP, hypertension; volume-related [2]
- Septic transfusion reaction: High fever, rigors, hypotension; Gram stain and culture of product positive; most common with platelets (stored at room temperature) [5]
- Transfusion-associated dyspnea (TAD): Respiratory distress not meeting criteria for TRALI, TACO, or allergic reaction [2]
- Non-transfusion-related anaphylaxis: Drug reaction, latex allergy, or other concurrent allergen exposure
Key distinguishing features: Isolated urticaria/pruritus without fever strongly favors allergic reaction. Fever without rash favors FNHTR. Fever + hemodynamic instability + dark urine = hemolytic reaction until proven otherwise. [1][6]
9. Past Medical History
- Prior transfusion reactions (type, severity, treatment required)
- Known IgA or haptoglobin deficiency
- Atopic diseases (asthma, eczema, allergic rhinitis, food allergies)
- Hematologic conditions requiring chronic transfusion (MDS, sickle cell, thalassemia, leukemia)
- Prior anaphylaxis to any cause
- Autoimmune conditions
- Mastocytosis or mast cell disorders
10. Physical Exam
Vital Signs
- Mild reactions: Vitals typically stable; no fever
- Anaphylaxis: Hypotension, tachycardia, tachypnea, oxygen desaturation
Focused Exam
- Skin: Urticaria (wheals), erythema, flushing, angioedema (lips, eyelids, tongue), maculopapular rash [2]
- Airway: Stridor, tongue/lip swelling, oropharyngeal edema
- Lungs: Wheezing, decreased air entry (bronchospasm); bilateral crackles suggest TACO or TRALI rather than allergic reaction
- Cardiovascular: Tachycardia, hypotension, weak pulses
- Abdomen: Distension, tenderness (GI involvement in anaphylaxis)
- Absence of flank tenderness and jaundice helps exclude hemolytic reaction
11. Lab Studies
Routine for any suspected transfusion reaction
- Repeat type and crossmatch (clerical check for ABO compatibility)
- Direct antiglobulin test (DAT/Coombs) — should be negative in allergic reactions; positive suggests hemolytic reaction [6]
- CBC with peripheral smear
- Visual inspection of plasma and urine for hemolysis (pink/red plasma, dark urine)
- Free hemoglobin (plasma and urine) — should be negative in allergic reactions
If anaphylaxis suspected
- Serum tryptase (drawn within 1–3 hours of reaction onset; elevated in anaphylaxis)
- IgA level and anti-IgA antibodies — especially after anaphylactic reactions or recurrent severe allergic reactions [1]
- Haptoglobin level — both to evaluate for hemolysis and to screen for haptoglobin deficiency [1]
Expected findings in isolated allergic reaction: All hemolysis workup negative; tryptase may be elevated in anaphylaxis.
12. Imaging
- Not routinely indicated for mild allergic reactions
- Chest X-ray: Indicated if respiratory distress is present — to differentiate from TRALI (bilateral infiltrates, no cardiomegaly) and TACO (pulmonary edema, cardiomegaly, pleural effusions) [5]
- CT chest/neck: Rarely needed; consider if concern for airway compromise not responding to treatment
13. Special Tests
- Serum tryptase: Best drawn 15 minutes to 3 hours after symptom onset; supports mast cell degranulation/anaphylaxis diagnosis
- IgA quantification and anti-IgA antibody testing: Indicated after anaphylactic transfusion reactions to identify IgA-deficient patients [1]
- Haptoglobin phenotyping: In populations with higher prevalence of ahaptoglobinemia (East Asian descent) [1]
- Blood bank investigation: Return remaining blood product and tubing to blood bank for Gram stain, culture, and serologic workup per institutional protocol [5]
- Hemovigilance reporting: All transfusion reactions should be reported to the institutional hemovigilance system [5]
14. ECG
- Indicated in anaphylaxis or any hemodynamic instability during transfusion reaction
- Look for: Sinus tachycardia, ST changes (Kounis syndrome — allergic angina), arrhythmias
- Not routinely needed for mild cutaneous-only reactions
- Helps differentiate from cardiac causes of dyspnea/hypotension in the differential
15. Assessment
Severity Classification: [1][8]
- Mild: Isolated cutaneous symptoms (urticaria, pruritus, flushing, localized angioedema) — most common presentation (~70% present with urticaria) [2]
- Moderate: Cutaneous symptoms plus mild systemic features (generalized urticaria, mild bronchospasm responsive to treatment)
- Severe/Anaphylaxis: Systemic reaction with bronchospasm, laryngeal edema, hypotension, cardiovascular collapse — incidence ~8 per 100,000 units [1]
Key clinical pearls
- Allergic reactions are a clinical diagnosis — no confirmatory lab test exists for mild reactions
- The absence of fever is a key distinguishing feature from FNHTR and hemolytic reactions
- Recurrence risk increases with each subsequent reaction [3]
- Complications: Airway compromise, cardiovascular collapse, death (rare, primarily with anaphylaxis)
16. Treatment Plan
Immediate Management (All Reactions)
- Stop the transfusion (or pause for mild reactions)
- Maintain IV access with normal saline
- Assess ABCs and vital signs
Mild Allergic Reaction (Cutaneous Only)
- Diphenhydramine 25–50 mg IV (Grade 1A) [1]
- If symptoms resolve completely → may restart the same unit at a slower rate under direct observation [1]
- Discontinue permanently if symptoms recur or progress beyond skin [1]
Anaphylaxis
- Epinephrine 0.3–0.5 mg IM (1:1,000) into anterolateral thigh — repeat every 5–15 minutes as needed (Grade 1A) [1]
- Aggressive IV fluid resuscitation (NS bolus)
- Supplemental oxygen / airway management
- Second-line agents: [1]
- Diphenhydramine 50 mg IV
- Famotidine 20 mg IV (H2 blocker)
- Albuterol nebulization for bronchospasm
- Methylprednisolone 125 mg IV or hydrocortisone 200 mg IV
- Consider epinephrine infusion for refractory hypotension
- Do NOT restart the transfusion
Future Transfusion Prevention (for patients with history of moderate-to-severe ATR):
- Premedication: Antihistamines ± corticosteroids (evidence supports benefit specifically in patients with prior severe ATR) [1][3]
- Washed blood products: Removes plasma proteins/allergens (Grade 1C) [1][9]
- Platelets in additive solutions: Reduced plasma content [1]
- IgA-deficient products: For confirmed IgA-deficient patients with anti-IgA antibodies [1]
- Omalizumab: Case reports support use in refractory platelet-induced anaphylaxis [10]
17. Disposition
Discharge criteria (mild reactions)
- Isolated cutaneous symptoms that resolve completely with antihistamines
- Stable vital signs for ≥30 minutes after symptom resolution
- Transfusion completed or appropriately discontinued
- Patient educated on reaction and future transfusion precautions
Observation/Admission criteria
- Moderate reactions with systemic features — observe for minimum 4–6 hours
- Any respiratory symptoms, even if resolved
- Recurrent reactions during the same transfusion episode
ICU admission criteria
- Anaphylaxis requiring epinephrine
- Hemodynamic instability
- Airway compromise
- Biphasic anaphylaxis concern (observe 6–12 hours minimum)
Specialist consultation triggers
- Anaphylactic reaction → Allergy/Immunology and Transfusion Medicine/Blood Bank [1]
- Recurrent moderate-to-severe reactions → Transfusion Medicine for product modification planning
- Suspected IgA deficiency → Immunology workup [1]
- Diagnostic uncertainty (TRALI vs. TACO vs. allergic) → Pulmonology/Critical Care
18. Follow Up / Return Precautions
Follow-up
- Blood bank notification and hemovigilance report filed for all reactions [5]
- Transfusion reaction documented in medical record with severity grading
- For anaphylaxis: Follow-up with Allergy/Immunology within 2–4 weeks for IgA level, anti-IgA antibodies, tryptase, and haptoglobin testing [1]
- For recurrent reactions: Transfusion Medicine consultation to establish a transfusion plan (premedication protocol, washed products, additive solution platelets) [1][3]
Return precautions (counsel patient)
- Return immediately for: Difficulty breathing, throat swelling, hives spreading, dizziness/lightheadedness, chest pain, fever/chills
- Carry documentation of transfusion reaction type and severity for future transfusions
- Patients with anaphylaxis should be prescribed an epinephrine auto-injector if ongoing transfusion needs are anticipated
Expected course
- Mild reactions typically resolve within 30–60 minutes with antihistamines
- Anaphylaxis: Most patients stabilize within hours with appropriate treatment; biphasic reactions can occur up to 12 hours later
- Recurrence with future transfusions is common without preventive measures [3]
Images
References
1. Transfusion Reactions: Prevention, Diagnosis, and Treatment. — Delaney M, Wendel S, Bercovitz RS, et al. Lancet. 2016.
2. Epidemiology of Pediatric Transfusion Reactions. — Stone EF, Chacreton D, Jimenez A, et al. JAMA Network Open. 2026.
3. History Matters: Preventing Severe Allergic Transfusion Reactions. — Wappler-Guzzetta EA, Shafiq A, Asad U, Chakravarty T, Nedelcu EG. American Journal of Clinical Pathology. 2025.
4. Immunological Complications of Blood Transfusion: Current Insights and Advances. — Bansal N, Raturi M, Singh C, Bansal Y. Current Opinion in Immunology. 2025.
5. Blood Transfusion Reactions-a Comprehensive Review of the Literature Including a Swiss Perspective. — Ackfeld T, Schmutz T, Guechi Y, Le Terrier C. Journal of Clinical Medicine. 2022.
6. Hemolytic Transfusion Reactions. — Panch SR, Montemayor-Garcia C, Klein HG. The New England Journal of Medicine. 2019.
7. Premedication for the Prevention of Nonhemolytic Transfusion Reactions: A Systematic Review and Meta-Analysis. — Ning S, Solh Z, Arnold DM, Morin PA. Transfusion. 2019.
8. Pharmacological Interventions for the Prevention of Allergic and Febrile Non-Haemolytic Transfusion Reactions. — Martí-Carvajal AJ, Solà I, González LE, Leon de Gonzalez G, Rodriguez-Malagon N. The Cochrane Database of Systematic Reviews. 2010.
9. Current Understanding of Allergic Transfusion Reactions: Incidence, Pathogenesis, Laboratory Tests, Prevention and Treatment. — Hirayama F. British Journal of Haematology. 2013.
10. Successful Management of Severe Allergic Reactions to Platelet Transfusion With Omalizumab: A Case Report. — Choi Y, Byun JM, Kim I, et al. Medicine. 2021.
11. Leukoreduction for the Prevention of Adverse Reactions From Allogeneic Blood Transfusion. — Simancas-Racines D, Osorio D, Martí-Carvajal AJ, Arevalo-Rodriguez I. The Cochrane Database of Systematic Reviews. 2015.